© 2021 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

Advertisement

#blood cancer

Yescarta, CAR-T, axicabtagene ciloleucel
CAR-T Therapy: Lifeline to A Cure?
Imbruvica Bests Chemotherapy for Older People With Leukemia
Blood Cancers 101

Survey Finds COVID-19 Vaccine Hesitancy Among Those With Blood Cancer Diagnosis

The vaccine hesitancy comes despite serious risks from COVID-19 for people diagnosed with blood cancers such as leukemia and lymphoma.
Multiple myeloma cells

FDA Approved Pepaxto for Heavily Treated Multiple Myeloma

Nearly a quarter of patients treated with the peptide-drug conjugate experienced partial remission.
Chimeric antigen receptor T-cell (CAR-T) therapy

What’s Next for T-cell Therapies: Q&A with Dr. Stanley Riddell

After approval of the latest cellular therapy for non-Hodgkin lymphoma, the big challenge is how to extend it to common solid tumors.

FDA Approves Ukoniq for Marginal Zone and Follicular Lymphoma

Umbralisib led to remission in 49% of patients with marginal zone lymphoma and 43% of those with follicular lymphoma.

People With Cancer Should Receive COVID-19 Vaccine, Experts Say

The coronavirus vaccines are safe and should be effective even for people with advanced cancer.
Aaron L. Moye, PhD

Damon Runyon’s Top 2020 Highlights in Cancer Research

Damon Runyon Cancer Research Foundation shares some exciting discoveries made by Damon Runyon researchers in 2020.
Myeloma cells (purple) in a patient's bone marrow, with a few normal cells in pink in the background.

FDA Approves Xpovio for Refractory or Relapsed Multiple Myeloma

Xpovio (selinexor) was approved for adults with multiple myeloma who have received at least one prior therapy.

COVID-19 and Cancer Treatment

Studies ask whether cancer treatment, such as chemotherapy and immunotherapy, can lead to more severe COVID-19.

Among Minorities, Poverty Raises Death Risk From Acute Myeloid Leukemia

Poorer outcomes for Black and Hispanic patients significantly depend on where they live.

Donor Stem Cell Transplant Improves Survival in Older Patients with Myelodysplastic Syndrome

Despite being the only current cure for MDS, transplants generally haven’t been offered to older patients.

Venclexta Added to Standard Treatments Shows Promise for High-Risk Myeloid Blood Cancers

The drug targets cancer’s survival proteins, making them more vulnerable to treatments that cause cancer cells to self-destruct.

Cancer Survivors at Greater Risk of Flu Complications

Those with blood cancers are nine times more likely to be hospitalized or die from the flu.

Study Sheds Light on Risk of Treatment-Related Blood Cancers

Some patients develop a secondary blood cancer after receiving radiation or chemotherapy treatment for their initial cancer diagnosis

The Results Are In!!

Some might say that rejoicing over my numbers at this stage is slightly premature.

The Mystery of it All

As my coughing has gotten more noticeable the last few nights, I have again become quite concerned. Could I have lung cancer too?

First Clinical Trial to Study Blood Cancer Patients with COVID-19

The trial will test the drug acalabrutinib in those with acute myeloid leukemia, acute lymphoblastic leukemia and myelodysplastic syndromes.
Advertisement
Science News
Features